Full-Year Sales Growth
Sales grew 7% in constant currency to GBP 1.7 billion for FY2025, with Q4 sales up 5% cc versus a strong comparator.
Adjusted Profit and EBITDA Expansion
Adjusted operating profit rose 8% to GBP 295 million and adjusted profit before tax increased 8% to GBP 276 million; EBITDA increased 5% to GBP 397 million.
Segment Outperformance – Consumer Care & F&F
Consumer Care grew 8% for the year and 9% in Q4; Fragrances & Flavors (F&F) was a standout, up ~15% for the year with strong regional/local customer demand.
Life Sciences and Crop Momentum
Life Sciences grew 8% for the year with Crop Protection up 14% (full year) and Seed Enhancement up 8%; Pharma delivered its strongest quarter, driven by higher excipient sales.
Innovation and Pipeline Progress
Sales of patented ingredients rose 9%; sales of new ingredients increased 10% in 2025 and average pipeline value per customer co-creation project increased 12%.
Improved Customer Metrics
Net Promoter Score improved by 11 points, with >90% customer retention over 5 years and top-quartile benchmarking for product quality, innovation and trust.
Margin Recovery and Transformation Benefit
Operating margin improved through the year (17.2% → 17.4% full year; second-half margin 17.6%) with a 1.6 percentage point benefit cited from transformation cost savings.
Free Cash Flow and Leverage
Free cash flow strengthened to GBP 162 million in FY2025; net debt reduced slightly to GBP 524 million with leverage improving to 1.3x EBITDA.
CapEx Discipline
CapEx reduced from GBP 138 million to GBP 108 million (below guidance of GBP 135 million), with a planned continuation around ~6% of sales.
Clear 3-Year Financial Framework
Management targets organic sales growth of c.3–6% (Consumer Care) and 4–7% (Life Sciences), adjusted operating margin >20% by 2028, free cash flow conversion >12% and ROIC >10%, plus GBP 100 million annualized transformation savings and GBP 50 million working capital reduction by 2028.